Omeros Corporation
Clinical trials sponsored by Omeros Corporation, explained in plain language.
-
New drug trial offers hope for rare blood disorder patients
Disease control TerminatedThis study tested whether the drug OMS721 (narsoplimab) could safely treat atypical hemolytic uremic syndrome (aHUS), a rare and serious blood disorder that can damage kidneys. The trial enrolled adults and adolescents with aHUS who either didn't respond well to standard plasma t…
Phase: PHASE3 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Apr 04, 2026 08:36 UTC
-
Race to slow silent kidney killer halted
Disease control TerminatedThis study tested whether the drug OMS721 (narsoplimab) could help control IgA nephropathy, a kidney disease that can lead to kidney failure. Researchers enrolled 360 adults with confirmed disease and significant protein in their urine to receive either the drug or a placebo. The…
Phase: PHASE3 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Experimental drug tested to control protein leak in damaged kidneys
Disease control TerminatedThis study tested whether an experimental drug called OMS721 (narsoplimab) was safe and could reduce protein in the urine for adults with certain serious kidney diseases. It involved 31 participants with conditions like IgA nephropathy, lupus nephritis, and others, who received t…
Phase: PHASE2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC